These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 15703432)

  • 21. Disseminated tuberculosis in a Crohn's disease patient on anti-TNF alpha therapy despite chemoprophylaxis.
    Bourikas LA; Kourbeti IS; Koutsopoulos AV; Koutroubakis IE
    Gut; 2008 Mar; 57(3):425; author reply 425-6. PubMed ID: 18268059
    [No Abstract]   [Full Text] [Related]  

  • 22. [What can be expected from biological therapies for Crohn's disease?].
    Lemann M
    Gastroenterol Clin Biol; 2001 Nov; 25(11):945-7. PubMed ID: 11845043
    [No Abstract]   [Full Text] [Related]  

  • 23. How deep is remission in perianal Crohn's disease and do imaging modalities matter?
    Savoye G; Savoye-Collet C
    Am J Gastroenterol; 2010 Jun; 105(6):1445-6; author reply 1446. PubMed ID: 20523317
    [No Abstract]   [Full Text] [Related]  

  • 24. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease.
    Martínez-Borra J; López-Larrea C; González S; Fuentes D; Dieguez A; Deschamps EM; Pérez-Pariente JM; López-Vázquez A; de Francisco R; Rodrigo L
    Am J Gastroenterol; 2002 Sep; 97(9):2350-6. PubMed ID: 12358255
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sarcoidosis during infliximab therapy for Crohn's disease.
    Takahashi H; Kaneta K; Honma M; Ishida-Yamamoto A; Ashida T; Kohgo Y; Ohsaki Y; Iizuka H
    J Dermatol; 2010 May; 37(5):471-4. PubMed ID: 20536653
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Infliximab (Remicade), a new biological treatment for Crohn's disease.
    D'Haens GR
    Ital J Gastroenterol Hepatol; 1999; 31(6):519-20. PubMed ID: 10575573
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ABT-874, a fully human monoclonal anti-IL-12/IL-23 antibody for the potential treatment of autoimmune diseases.
    Ding C; Xu J; Li J
    Curr Opin Investig Drugs; 2008 May; 9(5):515-22. PubMed ID: 18465662
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Secondary amyloidosis in Crohn's disease: treatment with tumour necrosis factor inhibitor.
    Boscá MM; Pérez-Baylach CM; Solis MA; Antón R; Mayordomo E; Pons S; Mínguez M; Benages A
    Gut; 2006 Feb; 55(2):294-5. PubMed ID: 16407390
    [No Abstract]   [Full Text] [Related]  

  • 29. Early combined immunosuppression in Crohn's disease.
    Danese S; Peyrin-Biroulet L
    Lancet; 2008 Jun; 371(9629):1996; author reply 1996-7. PubMed ID: 18555908
    [No Abstract]   [Full Text] [Related]  

  • 30. A review of the impact of biologics on surgical complications in Crohn's disease.
    Chang MI; Cohen BL; Greenstein AJ
    Inflamm Bowel Dis; 2015 Jun; 21(6):1472-7. PubMed ID: 25811432
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-TNF therapies have eliminated the need for steroids in pediatric Crohn's disease: pro. Why use steroids if safer therapies are available?
    Baldassano RN
    Inflamm Bowel Dis; 2001 Nov; 7(4):338-41; discussion 345-6. PubMed ID: 11720326
    [No Abstract]   [Full Text] [Related]  

  • 32. Anti-TNF antibody treatment of Crohn's disease.
    van Deventer SJ
    Ann Rheum Dis; 1999 Nov; 58 Suppl 1(Suppl 1):I114-20. PubMed ID: 10577987
    [No Abstract]   [Full Text] [Related]  

  • 33. Anti-TNF therapies have eliminated the need for steroids in pediatric Crohn's disease: con. Why use a drug with an unknown long-term safety profile if more established therapies will be effective?
    Griffiths AM
    Inflamm Bowel Dis; 2001 Nov; 7(4):342-4; discussion 345-6. PubMed ID: 11720327
    [No Abstract]   [Full Text] [Related]  

  • 34. Anti-tumor necrosis factor alpha: Crohn's disease guided missile.
    Bitton A
    Inflamm Bowel Dis; 1998 May; 4(2):173-4. PubMed ID: 9589305
    [No Abstract]   [Full Text] [Related]  

  • 35. Esophagogastric Crohn's Disease Manifested by Life-Threatening Odynophagia and Chest Pain: a Case Report.
    So H; Park BH; Jang K; Baek H; Kim YJ
    J Korean Med Sci; 2018 Jan; 33(4):e30. PubMed ID: 29318797
    [No Abstract]   [Full Text] [Related]  

  • 36. Letter: Early real-world evidence from the United Arab Emirates of the persistence, effectiveness and safety of risankizumab for the treatment of Crohn's disease.
    Alahmad M; Quraishi MN; Khan SW; Omar NM; Malik TA
    Aliment Pharmacol Ther; 2024 Jul; 60(1):101-102. PubMed ID: 38779929
    [No Abstract]   [Full Text] [Related]  

  • 37. Risankizumab for Crohn's disease.
    Hibi T
    Lancet; 2022 May; 399(10340):1992-1993. PubMed ID: 35644143
    [No Abstract]   [Full Text] [Related]  

  • 38. Targeting Crohn's disease.
    Hanauer SB
    Lancet; 2017 Dec; 390(10114):2742-2744. PubMed ID: 29096947
    [No Abstract]   [Full Text] [Related]  

  • 39. [Risankizumab in patients with Crohn's disease].
    Blumenstein I; Nitschmann S
    Inn Med (Heidelb); 2023 Jan; 64(1):102-106. PubMed ID: 36515721
    [No Abstract]   [Full Text] [Related]  

  • 40. Recombinant interleukin 10 for the treatment of active Crohn's disease: lessons in biologic therapy.
    Bickston SJ; Cominelli F
    Gastroenterology; 2000 Dec; 119(6):1781-3. PubMed ID: 11113101
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.